<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02877082</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00082499</org_study_id>
    <secondary_id>NCI-2016-01035</secondary_id>
    <secondary_id>Winship3258-16</secondary_id>
    <nct_id>NCT02877082</nct_id>
  </id_info>
  <brief_title>Tacrolimus, Bortezomib, &amp; Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients</brief_title>
  <official_title>Phase II Trial of Low Toxicity GVHD Prevention and Enhanced Immune Recovery With Tacrolimus, Bortezomib and ThymoglobulinÂ® TBT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well tacrolimus, bortezomib, and anti-thymocyte globulin
      (thymoglobulin) work in preventing low toxicity graft versus host disease (GVHD) in patients
      with blood cancer who are undergoing donor stem cell transplant. Tacrolimus and
      anti-thymocyte globulin may reduce the risk of the recipient's body rejecting the transplant
      by suppressing the recipient's immune system. Giving bortezomib after the transplant may help
      prevent GVHD by stopping the donor's cells from attacking the recipient. Giving tacrolimus,
      bortezomib, and anti-thymocyte globulin may be a better way to prevent low toxicity GVHD in
      patients with blood cancer undergoing donor stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine a composite end point of alive and severe acute GVHD free at 6 months
      following human leukocyte antigen (HLA) matched related or unrelated donor hematopoietic
      peripheral blood transplant in patients with hematologic malignancies who receive the
      immunosuppressive combination tacrolimus, bortezomib, anti-thymocyte globulin (TBT) as GVHD
      prophylaxis.

      II. To determine the safety of this combination in the first six months post-transplant.

      SECONDARY OBJECTIVES:

      I. To determine the cumulative incidence of grade III-IV aGVHD.

      II. To determine incidence and severity of chronic GVHD.

      III. To determine disease relapse or progression overall and disease free survival at one
      year.

      OUTLINE:

      Patients receive tacrolimus intravenously (IV) on day -3 through day 180. Patients may
      receive tacrolimus orally (PO) later at the doctor's discretion. Patients receive
      anti-thymocyte globulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3.
      Patients undergo allogeneic bone marrow transplant on day 0.

      After completion of study treatment, patients are followed up for 6 months and then
      periodically for up to 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Serious Adverse Events and Adverse Events Related to This Immunosuppressive Regimen</measure>
    <time_frame>Up to 6 months post-transplant</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical experience or change of an existing condition that occurs during or after treatment. All AEs occurring during this study, whether observed by the physician, nurse, or reported by the patient, will be graded per NCI CTCAE version 4.0 and recorded on protocol-specific case report forms. A serious adverse event (SAE) is defined as any expected or unexpected adverse event (AE, generally equivalent to CTCAE grades 3, 4 or 5) that results in any of the following outcomes:
Death
Life-threatening event
In-patient hospitalization (not required as part of the treatment) or prolongation of existing hospitalization
Persistent or significant disability/incapacity
Congenital anomaly/birth defect
Cancer
Overdose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Alive and Free of Severe Acute GVHD Following HLA Matched Related or Unrelated Donor Hematopoietic Peripheral Blood Transplant</measure>
    <time_frame>At 6 months post-transplant</time_frame>
    <description>Will use patient counts for the number of patients alive and free of severe acute graft versus host disease (GVHD) following human leukocyte antigen (HLA) matched related or unrelated donor hematopoietic peripheral blood transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Grade III-IV aGVHD</measure>
    <time_frame>Up to 2 years post-transplant</time_frame>
    <description>Will be summarized as percentage and 95% confidence level will be also constructed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic GVHD</measure>
    <time_frame>Up to 2 years post-transplant</time_frame>
    <description>Will be summarized as percentage and 95% confidence level will be also constructed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At 1 year post-transplant</time_frame>
    <description>Will be analyzed with Kaplan Meier method and Logrank test.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelofibrosis</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tacrolimus, bortezomib, thymoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctor's discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Tacrolimus, bortezomib, thymoglobulin</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>ATS</other_name>
    <other_name>Anti-Thymocyte Globulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Tacrolimus, bortezomib, thymoglobulin</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
    <other_name>PS341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Tacrolimus, bortezomib, thymoglobulin</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute leukemia, chronic myelogenous leukemia, myeloproliferative
             disorder and myelodysplasia with no circulating blasts and with less than 5% blasts in
             the bone marrow within 4 weeks of the start of transplant conditioning regimen

          -  Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma; follicular,
             marginal zone, diffuse large B-cell or mantle cell lymphoma with chemo-sensitive
             disease at time of transplant

          -  Patients must have a related or unrelated peripheral blood stem cell donor; sibling
             donor must be a 6/6 match for human leukocyte antigen (HLA)-A and -B at intermediate
             (or higher) resolution, and -DRB1 at high resolution using deoxyribonucleic acid
             (DNA)-based typing, and must be willing to donate peripheral blood stem cells and meet
             institutional criteria for donation; unrelated donor must be 8/8 match at HLA-A, -B,
             -C and -DRB1 at high resolution using DNA-based typing; unrelated donor must be
             willing to donate peripheral blood stem cells and be medically eligible to donate stem
             cells according to National Marrow Donor Program (NMDP) criteria

          -  Cardiac function: ejection fraction &gt; 40%

          -  Estimated creatinine clearance greater than 50 mL/minute (using the Cockcroft-Gault
             formula and actual body weight)

          -  Pulmonary function: carbon monoxide diffusing capability test (DLCO) â¥ 40% (adjusted
             for hemoglobin) and forced expiratory volume in 1 second (FEV1) â¥ 50%

          -  Total bilirubin &lt; 1.5 x the upper limit of normal; patients who have been diagnosed
             with Gilbert's disease are allowed to exceed the defined bilirubin value of 1.5 x the
             upper limit of normal

          -  Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) &lt; 2.5 x the upper
             normal limit

          -  Female subjects (unless postmenopausal for at least 1 year before the screening visit,
             or surgically sterilized), agree to practice two effective methods of contraception or
             agree to completely abstain from heterosexual intercourse from the time of signing the
             informed consent through 12 months post-transplant

          -  Male subjects (even if surgically sterilized), of partners of women of childbearing
             potential must agree to practice effective barrier contraception or abstain from
             heterosexual intercourse from the time of signing the informed consent through 12
             months post-transplant

          -  Signed informed consent

        Exclusion Criteria:

          -  Prior allogeneic transplant

          -  Karnofsky performance score &lt; 70%

          -  Active central nervous system (CNS) involvement by malignant cells

          -  Patients with uncontrolled bacterial, viral, or fungal infections (currently taking
             medication and with progression or no clinical improvement) at time of enrollment

          -  Patients with transformed lymphoma (e.g., Richter's transformation arising in
             follicular lymphoma or chronic lymphocytic leukemia)

          -  Patients seropositive for the human immunodeficiency virus (HIV)

          -  Patient with active hepatitis B or C

          -  Patients with hypersensitivity to bortezomib, boron, or mannitol

          -  Patients with &gt; grade 2 sensory peripheral neuropathy

          -  Myocardial infarction within 6 months prior to enrollment or New York Heart
             Association (NYHA) class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities; prior to study entry, any
             electrocardiography (ECG) abnormality at screening must be documented by the
             investigator as not medically relevant

          -  Female patients who are lactating or pregnant

          -  Patients with a serious medical or psychiatric illness likely to interfere with
             participation in this clinical study

          -  Patients with prior malignancies, except resected basal cell carcinoma or treated
             cervical carcinoma in situ; cancer treated with curative intent &gt; 5 years previously
             will be allowed; cancer treated with curative intent &lt; 5 years previously will not be
             allowed unless approved by the protocol officer or one of the protocol chairs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaid Al-Kadhimi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University/Winship Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2016</study_first_submitted>
  <study_first_submitted_qc>August 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <results_first_submitted>February 16, 2018</results_first_submitted>
  <results_first_submitted_qc>March 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2018</results_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Zaid Al-Kadhimi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from 9/9/2016 to 7/11/2017 at Winship Cancer Institute of Emory University.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tacrolimus, Bortezomib, Thymoglobulin</title>
          <description>Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctorâs discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
Thymoglobulin: Given IV
Bortezomib: Given IV
Tacrolimus: Given IV and PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Trial was closed early</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tacrolimus, Bortezomib, Thymoglobulin</title>
          <description>Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctorâs discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
Thymoglobulin: Given IV
Bortezomib: Given IV
Tacrolimus: Given IV and PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Serious Adverse Events and Adverse Events Related to This Immunosuppressive Regimen</title>
        <description>An adverse event (AE) is defined as any untoward medical experience or change of an existing condition that occurs during or after treatment. All AEs occurring during this study, whether observed by the physician, nurse, or reported by the patient, will be graded per NCI CTCAE version 4.0 and recorded on protocol-specific case report forms. A serious adverse event (SAE) is defined as any expected or unexpected adverse event (AE, generally equivalent to CTCAE grades 3, 4 or 5) that results in any of the following outcomes:
Death
Life-threatening event
In-patient hospitalization (not required as part of the treatment) or prolongation of existing hospitalization
Persistent or significant disability/incapacity
Congenital anomaly/birth defect
Cancer
Overdose</description>
        <time_frame>Up to 6 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus, Bortezomib, Thymoglobulin</title>
            <description>Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctorâs discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
Thymoglobulin: Given IV
Bortezomib: Given IV
Tacrolimus: Given IV and PO</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Serious Adverse Events and Adverse Events Related to This Immunosuppressive Regimen</title>
          <description>An adverse event (AE) is defined as any untoward medical experience or change of an existing condition that occurs during or after treatment. All AEs occurring during this study, whether observed by the physician, nurse, or reported by the patient, will be graded per NCI CTCAE version 4.0 and recorded on protocol-specific case report forms. A serious adverse event (SAE) is defined as any expected or unexpected adverse event (AE, generally equivalent to CTCAE grades 3, 4 or 5) that results in any of the following outcomes:
Death
Life-threatening event
In-patient hospitalization (not required as part of the treatment) or prolongation of existing hospitalization
Persistent or significant disability/incapacity
Congenital anomaly/birth defect
Cancer
Overdose</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Alive and Free of Severe Acute GVHD Following HLA Matched Related or Unrelated Donor Hematopoietic Peripheral Blood Transplant</title>
        <description>Will use patient counts for the number of patients alive and free of severe acute graft versus host disease (GVHD) following human leukocyte antigen (HLA) matched related or unrelated donor hematopoietic peripheral blood transplant.</description>
        <time_frame>At 6 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus, Bortezomib, Thymoglobulin</title>
            <description>Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctorâs discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
Thymoglobulin: Given IV
Bortezomib: Given IV
Tacrolimus: Given IV and PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive and Free of Severe Acute GVHD Following HLA Matched Related or Unrelated Donor Hematopoietic Peripheral Blood Transplant</title>
          <description>Will use patient counts for the number of patients alive and free of severe acute graft versus host disease (GVHD) following human leukocyte antigen (HLA) matched related or unrelated donor hematopoietic peripheral blood transplant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Grade III-IV aGVHD</title>
        <description>Will be summarized as percentage and 95% confidence level will be also constructed.</description>
        <time_frame>Up to 2 years post-transplant</time_frame>
        <population>Data were not collected because trial closed early.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus, Bortezomib, Thymoglobulin</title>
            <description>Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctorâs discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
Thymoglobulin: Given IV
Bortezomib: Given IV
Tacrolimus: Given IV and PO</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Grade III-IV aGVHD</title>
          <description>Will be summarized as percentage and 95% confidence level will be also constructed.</description>
          <population>Data were not collected because trial closed early.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Chronic GVHD</title>
        <description>Will be summarized as percentage and 95% confidence level will be also constructed.</description>
        <time_frame>Up to 2 years post-transplant</time_frame>
        <population>Data were not collected because trial closed early.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus, Bortezomib, Thymoglobulin</title>
            <description>Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctorâs discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
Thymoglobulin: Given IV
Bortezomib: Given IV
Tacrolimus: Given IV and PO</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Chronic GVHD</title>
          <description>Will be summarized as percentage and 95% confidence level will be also constructed.</description>
          <population>Data were not collected because trial closed early.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Will be analyzed with Kaplan Meier method and Logrank test.</description>
        <time_frame>At 1 year post-transplant</time_frame>
        <population>Data were not collected because trial closed early.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus, Bortezomib, Thymoglobulin</title>
            <description>Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctorâs discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
Thymoglobulin: Given IV
Bortezomib: Given IV
Tacrolimus: Given IV and PO</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Will be analyzed with Kaplan Meier method and Logrank test.</description>
          <population>Data were not collected because trial closed early.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected up to 180 days post-transplant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tacrolimus, Bortezomib, Thymoglobulin</title>
          <description>Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctorâs discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
Thymoglobulin: Given IV
Bortezomib: Given IV
Tacrolimus: Given IV and PO</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>After monitoring early toxicity and hyperacute severe acute graft versus host disease in 4/5 patients, it was decided to close this protocol.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Zaid Al-Kadhimi, MD</name_or_title>
      <organization>Emory University/Winship Cancer Institute</organization>
      <phone>404-778-1900</phone>
      <email>zalkadh@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

